Level Four Advisory Services’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Level Four Advisory Services’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,076	Closed	-$220K	–	915
2024 Q1	$220K	Buy	3,076 +80	+3%	+$5.5K	0.01%	696
2023 Q4	$215K	Buy	+2,996	New	+$172K	0.01%	701
2023 Q3	–	Sell	-7,483	Closed	-$474K	–	871
2023 Q2	$474K	Buy	+7,483	New	+$466K	0.03%	484
2023 Q1	–	Sell	-7,052	Closed	-$373K	–	833
2022 Q4	$373K	Sell	7,052 -398	-5%	-$19.9K	0.03%	466
2022 Q3	$347K	Sell	7,450 -6,975	-48%	-$364K	0.03%	392
2022 Q2	$823K	Sell	14,425 -237	-2%	-$13.4K	0.08%	250
2022 Q1	$897K	Buy	+14,662	New	+$761K	0.07%	263

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Level Four Advisory Services's ITCI Position: Q2 2024 in Review

Level Four Advisory Services sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2024, closing a stake of 3,076 shares — an estimated $220K sold.

Level Four Advisory Services first reported a position in ITCI in Q1 2022 and held it in 7 quarters. The position peaked at $897K in Q1 2022. 375 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.

Level Four Advisory Services reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2024 after selling out during the quarter.
Level Four Advisory Services sold 3,076 Intra-Cellular Therapies Inc. shares in Q2 2024, an estimated $220K.
Level Four Advisory Services first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 7 quarters.
Level Four Advisory Services's Intra-Cellular Therapies Inc. position peaked at $897K in Q1 2022.
375 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.

Based on Level Four Advisory Services's 13F filing for Q2 2024, filed 9 Aug 2024.